Mirum Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $521.3M | $336.9M | $186.4M | $77.1M | $19.1M |
| Operating income | -$22.1M | -$87.6M | -$109.2M | -$131.2M | -$173.4M |
| Operating expenses | $543.4M | $424.5M | $295.5M | $208.3M | $192.6M |
| Cash from operations | $55.8M | $10.3M | -$70.9M | -$120.1M | -$132.8M |
| Capital expenditure | $954,000 | $993,000 | $109,000 | $278,000 | $24,000 |
| Free cash flow | $54.9M | $9.3M | -$71.1M | -$120.4M | -$132.8M |
| Total assets | $842.8M | $670.8M | $646.6M | $352.9M | $294.7M |
| Total liabilities | $528.1M | $445.1M | $398.0M | $210.9M | $174.4M |
Shares outstanding 61.0M · Free float 96.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.